agenT-797

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed/Refractory Multiple Myeloma

Conditions

Relapsed/Refractory Multiple Myeloma

Trial Timeline

Mar 29, 2021 → May 31, 2023

NCT ID

NCT04754100

About agenT-797

agenT-797 is a phase 1 stage product being developed by MiNK Therapeutics for Relapsed/Refractory Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT04754100. Target conditions include Relapsed/Refractory Multiple Myeloma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04754100	Phase 1	Completed	Mar 29, 2021	May 31, 2023	Relapsed/Refractory Multiple Myeloma
NCT04582201	Phase 1	Completed	Sep 21, 2020	Apr 23, 2023	Respiratory Distress Syndrome, Adult

Competing Products

20 competing products in Relapsed/Refractory Multiple Myeloma

See all competitors

Product	Company	Stage	Hype Score
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	52
Eribulin mesylate	Eisai	Phase 2	52
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab	Eli Lilly	Phase 1/2	41
ISB 1342	Glenmark Pharmaceuticals	Phase 1	33
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide	Jiangsu Hengrui Medicine	Phase 3	77
Linperlisib ； Rituximab	Jiangsu Hengrui Medicine	Phase 1/2	41
Epcoritamab + Epcoritamab, lenalidomide and rituximab	AbbVie	Phase 2	52
Etentamig	AbbVie	Phase 1	33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax	AbbVie	Phase 3	77
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab	AbbVie	Phase 1	33
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	33
ABT-199 + bortezomib + dexamethasone	AbbVie	Phase 1	33
Venetoclax + Dexamethasone	AbbVie	Phase 1/2	41
ABBV-453 + Dexamethasone + Daratumumab + Lenalidomide	AbbVie	Phase 1	33
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	33
AZD4573	AstraZeneca	Phase 2	52
Moxetumomab Pasudotox	AstraZeneca	Pre-clinical	23
Administration of AZD6738	AstraZeneca	Phase 1	33
Blinatumomab	Amgen	Phase 2	51

Other Products from MiNK Therapeutics

agenT-797 + Approved ICIsPhase 1

agenT-797Phase 1